WallStSmart

LeMaitre Vascular Inc (LMAT)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 1132% more annual revenue ($3.07B vs $249.60M). LMAT leads profitability with a 23.1% profit margin vs 16.1%. WST appears more attractively valued with a PEG of 2.89. LMAT earns a higher WallStSmart Score of 61/100 (C+).

LMAT

Buy

61

out of 100

Grade: C+

Growth: 8.7Profit: 7.5Value: 6.7Quality: 5.0

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LMATUndervalued (+26.1%)

Margin of Safety

+26.1%

Fair Value

$118.87

Current Price

$111.08

$7.79 discount

UndervaluedFair: $118.87Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LMAT4 strengths · Avg: 8.3/10
Profit MarginProfitability
23.1%9/10

Keeps 23 of every $100 in revenue as profit

Operating MarginProfitability
21.8%8/10

Strong operational efficiency at 21.8%

Revenue GrowthGrowth
15.7%8/10

15.7% revenue growth

EPS GrowthGrowth
41.4%8/10

Earnings expanding 41.4% YoY

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

LMAT2 concerns · Avg: 2.0/10
PEG RatioValuation
3.072/10

Expensive relative to growth rate

P/E RatioValuation
43.7x2/10

Premium valuation, high expectations priced in

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : LMAT

The strongest argument for LMAT centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 23.1% and operating margin at 21.8%. Revenue growth of 15.7% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : LMAT

The primary concerns for LMAT are PEG Ratio, P/E Ratio. A P/E of 43.7x leaves little room for execution misses.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

LMAT profiles as a growth stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

LMAT is growing revenue faster at 15.7% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

LMAT scores higher overall (61/100 vs 55/100), backed by strong 23.1% margins and 15.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

LeMaitre Vascular Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?